SCHEMBL18323604

SCHEMBL18323604

CCOc1cc(C(=O)OC)cc2nnc(C)n12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 3/20 0.39
CREBBP Q92793 1/20 0.38
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
LMNA P02545 2/20 0.35
POLB P06746 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
GAA P10253 1/20 0.35
NFKB1 P19838 1/20 0.35
XDH P47989 1/20 0.35
GFER P55789 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
FUT7 Q11130 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18323595 0.86 KDM4E (0.44) KDM4ESMN1; SMN2ALDH1A1CA12CA1
SCHEMBL18323621 0.85 TSHR (0.44) KDM4EALDH1A1LMNAPOLBKMT2A
SCHEMBL15907128 0.83 CREBBP (0.36) KDM4ESMN1; SMN2ALDH1A1CREBBPCA12
SCHEMBL18323588 0.80 KDM4E (0.51) KDM4ESMN1; SMN2ALDH1A1CA12CA1
SCHEMBL18323589 0.78 KDM4E (0.38) KDM4ESMN1; SMN2ALDH1A1CA12CA1
SCHEMBL18323603 0.77 KDM4E (0.41) KDM4ESMN1; SMN2ALDH1A1CA12CA1
SCHEMBL18323592 0.76 KDM5A (0.39) KDM4ESMN1; SMN2ALDH1A1CA12CA1
SCHEMBL18323644 0.76 KDM4E (0.55) KDM4ESMN1; SMN2L3MBTL1KMT2A
SCHEMBL18323631 0.75 KDM4E (0.40) KDM4ESMN1; SMN2ALDH1A1CA12CA1
SCHEMBL18323607 0.74 KDM4E (0.41) KDM4ESMN1; SMN2ALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed